Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARK: UFT vs BCG Maintenance for Superficial Bladder Cancer
NCT01082510Phase 3Unknown
- Sponsor
- Urological Oncology Council of Northern Tokyo
- Start
- Jan 2010
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur + uracil in bladder cancer (2 arms), sponsored by Urological Oncology Council of Northern Tokyo. Primary endpoint: Relapse-free survival rate at 3 years. Status: unknown.
02
Drugs
tegafur + uracil
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT01082510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01082510.